PureTech Health PLC PureTech Capital Markets Meeting in London 9 May

TIDMPRTC

PureTech Health PLC

08 March 2017

PureTech Health Annual Capital Markets Meeting, London

Tuesday 9 May 2017

PureTech Health plc ("PureTech Health" or the "Company", LSE: PRTC), a cross-disciplinary biopharmaceutical company, announces its annual Capital Markets Meeting in London. The Company will discuss its near-term commercialisation and monetisation strategy as well as its growing research and development pipeline.

The meeting will take place in London on Tuesday 9 May 2017 from 13.00-17.00 BST and will feature PureTech Health presenters including members of the Company's Board of Directors and key scientific advisors.

Presenters at the event will include:

 
      --   Daphne Zohar, Co-Founder and CEO of PureTech 
            Health 
      --   Bharatt Chowrira, PhD, JD, President and Chief 
            of Business and Strategy of PureTech Health, 
            former President of Synlogic and former Chief 
            Operating Officer of Auspex Pharmaceuticals 
            (acquired by Teva Pharmaceuticals) 
      --   Joseph Bolen, PhD, Chief Scientific Officer 
            of PureTech Health; former President and Chief 
            Scientific Officer at Moderna Therapeutics 
            and former Chief Scientific Officer at Millennium 
            Pharmaceuticals (acquired by Takeda) 
      --   Atul Pande, MD, Chief Medical Officer of PureTech 
            Health, former SVP and Head of Neuroscience 
            at GlaxoSmithKline 
      --   Christopher Viehbacher, Independent Non-Executive 
            Director of PureTech Health; former CEO of 
            Sanofi 
      --   Raju Kucherlapati, PhD, Independent Non-Executive 
            Director, Scientific Advisory Board Member 
            of PureTech Health; Co-Founder of Millennium 
            Pharmaceuticals and Abgenix 
      --   John LaMattina, PhD, Independent Non-Executive 
            Director of PureTech Health; former President 
            of Pfizer Global Research and Development 
      --   Ben Shapiro, MD, Co-Founder & Non-Executive 
            Director of PureTech Health; former Executive 
            Vice President of Research for Merck 
      --   Marjorie Scardino, Senior Independent Director 
            of PureTech Health; former CEO of The Economist 
            and of Pearson plc, Chairman of the MacArthur 
            Foundation Board 
      --   Dennis A. Ausiello, M.D., PureTech Health 
            Scientific Advisory Board, Lead Director at 
            Pfizer, former Chief of Medicine at Massachusetts 
            General Hospital (Harvard) 
      --   Members of the PureTech Health leadership 
            team and senior leaders of Akili, Karuna, 
            Gelesis, Vedanta and other PureTech Health 
            platform companies

Please confirm if you would like to attend to PureTech.Event@fticonsulting.com

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical company creating 21(st) century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We have multiple human proof-of-concept studies and pivotal or registration studies expected to read out in the near-term. PureTech Health's rich and growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts who, along with PureTech's experienced team and board, analyse more than 650 scientific discoveries per year to identify and advance only the opportunities we believe hold the most promise for patients. This team and process place PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

 
   PureTech Health             FTI Consulting 
   Allison Mead                Ben Atwell, Matthew 
    +1 617 651 3156             Cole 
    amead@puretechhealth.com    +44 (0) 20 3727 
                                1000

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFMGGFMNLGNZZ

(END) Dow Jones Newswires

March 08, 2017 02:01 ET (07:01 GMT)

Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024